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Introduction
Indirect enzyme immunohistochemistry has become one of the most routine methods in histology and histopathology. In this procedure, the tissue is first incubated with a specific primary antibody, followed by a secondary antibody directed against the first and conjugated to an enzyme such as peroxidase (Nakane and Pierce, 1966) to allow enzymatic visualization of the immunostaining. More recent commonly used modifications are the peroxidase-antiperoxidase method (PAP) developed by Sternberger et al. (1970) and biotin-conjugated secondary antibodies followed by avidinconjugated peroxidase (ABC method) (Hsu et al., 1981) .
Despite the very widespread use of these techniques, there is only sketchy quantitative data available on the binding characteristics of polyclonal or monoclonal antibodies to their specific antigens under in situ conditions. Although many studies have also employed quantitative immunohistochemistry using a variety of autoradiographic ( h i s and Watson, 1989; Weissmann et al., 1989; Correa et al., 1988) and non-autoradiographic detection methods (Peretti-Ranucci et al., 1991; Benno et al., 1982) , the primary emphasis has been to set up a technique that allowed a reliable quantitative determination of antigen levels in situ.
In the present study we have turned our attention more to the binding characteristics of different monoclonal and polyclonal antibodies themselves, using the regenerating rat facial motor nucleus as the specific model. There are three main advantages of this model: first, axotomy of the facial nerve leads to a massive upregulation of a variety of antigens, such as C3bi complement receptor (CR3), vimentin, glial fibrillary acidic protein, and major histocompatibility complex antigens, in the facial nucleus (Streit et al., 1989; Kreutzberg, 1986,1988; Graeber et al., 1988) . Second, because of the distance between the axotomy site and the facial nucleus, the blood-brain barrier in the facial nucleus is not disrupted, so there is no deposition of serum proteins (e.g., immunoglobulins) that could cause crossreactivity and no observed invasion by hematogenous cells (Streit et al., 1988; Sjostrand, 1966) , allowing changes that occur after axotomy to be ascribed to the resident cells. Finally, the unoperated contralateral facial motor can serve as a specific intra-animal control. Here, we have made use of this model and autoradiography with [ 12SI]-iodinated secondary antibodies to characterize quantitatively the concentration defind the optimal concentrations of the antibodies and quantify changes that occur during nerve regeneration. These data are compared with those obtained by routine immunohistochemistry. ated by the Sigmaplot 3.1 statistics program (Jandel Scientific; Corte Madera. CA). This fit showed very good correlation with the plotted data over a 32-to 64-fold range in the radiation density (r2 = 0.99), and a further increase in the order of the polynomial fit (e.g., third order) did not lead to a marked improvement in the correlation coefficient. The radioactive density values obtained as BqImm' per 20 hm thick tissue sections were divided by the specific activity of the [ '251]-iodinated secondary antibody in BqIpg as indicated by the manufacturer and then converted to pg/mm3. Enzvme Immunohistochemistrv. Basicallv, the same procedures were ofthe in situ antibody binding,
Materials and Methods
Reagents. Ox-18 and Ox-42 monoclonal antibodies (ascites fluid) and an avidin-biotin kit were obtained from Camon (Wiesbaden, Germany), monoclonal antibodies against GFAP (G-A->) and vimentin (V9) from Boehringer (Mannheim, Germany), and polyclonal rabbit antibody against GFAP (2334) and the non-immune rabbit and goat sera from Dako (Hamburg, Germany) .
[ 12SI]-Iodinated secondary antibodies (sheep anti-mouse and donkey anti-rabbit immunoglobulins), [ 12rI] calibration standards, and [ 3H]-Ultrofilm were purchased from Amersham (Braunschweig, Germany). Purified IgG from normal, unimmunized mice and bovine serum albumin were from Sigma (Munich, Germany).
Animals and Surgical Procedures. Female Wistar rats (>200 g; 2-3 months old) were operated on under deep ether anesthesia. The right facial nerve was exposed and transected just beneath its exit from the stylomastoid foramen, and the animals were sacrificed at 2, 4, 7, 14, or 21 days after the operation. Unoperated animals served as Day 0 controls. Tissue Preparation. The brainstem was removed and rapidly frozen on a metal platform using expanding C02. Twenty-pm tissue sections were cut in a cryostat at the level of the facial motor nucleus, thaw-mounted onto glass slides, immediately frozen on dry ice, and stored at -80°C before use.
Quantitative Immunocytochemistry. All procedures were carried out at room temperature. The tissue sections were dried for 5-7 min. fixed for 5 min in 4% paraformaldehyde (Merck; Darmstadt, Germany) in a 10 mM sodium phosphate buffer (SPB), pH 7.4, and for 2 min each in 50% acetone/H20), 100% acetone, and 50% acetonelH20. The tissue sections were then washed in two changes of SPB (2 min each) and pre-incubated for 30 min at room temperature in 3% non-immune goat serum in SPB. They were then incubated for 2 h in a humid chamber with the primary antibody (diluted in SPB) and washed in two changes each of SPB supplemented with 1 mg/ml bovine serum albumin (SPBIBSA) and SPB. When several primary antibodies were used it was absolutely imperative to change the washing solutions and plastic ware after each individual antibody to prevent cross-contamination during washing. For the same reason, when dilution curves were performed, the tissue sections were washed in the order of increasing antibody concentration (i.e., decreasing dilution). The tissue sections were then incubated for 2 h with the secondary ['2rI]-iodinated antibody (stock solution 6 hg/ml) diluted 1:300 in SPB. To minimize nonspecific binding, the secondary antibody was pre-absorbed for 30-60 min 1:1 with non-immune Wistar rat Serum before dilution and application onto tissue sections. After incubation with secondary antibody, tissue sections were washed in three changes each of SPBIBSA and SPB and fixed overnight in a 2.5% glutaraldehyde/2% formaldehyde solution in SPB. After fixation, the tissue sections were washed in SPB, SPBIBSA, SPB, and two changes of bidistilled water, dried, overlaid with [ 3H]-Ultrofilm, and exposed for 3 weeks. Optical density was measured with the Tissue Analyzing System (TAS) from Leitz (Wetzlar, Germany), using a circular mask with 0.6 mm diameter as described by Raivich and Kreutzberg (1987) . The radioactive density was calculated from the optical density readings, using an inverse function algorithm from a calibration curve prepared by including [1251] calibration standards from Amersham during film exposure. This calibration curve was constructed by plotting optical density versus calibration standards on a log/log scale using a second-order polynomial fit gener-followed, up to the application of the secondary antibody, as described in the previous section. Here, biotin-conjugated horse anti-mouse immunoglobulin antibody, diluted at 1:lOO in SPB, was used as secondary antibody, and the tissue sections incubated for 2 lir and washed in SPB. Immunostaining was visualized by the avidin-biotin-peroxidase complex (ABC) method (Hsu et al., 1981) .
Statistical Analysis. The studies on the concentration dependence of antibody binding were performed 7 days after transection of the right facial nerve, using one animal per antibody (total of nine animals). Fortytwo brainstem tissue sections from each animal were grouped into three rows of 14 sections and numbered consecutively. Primary antibody was omitted from the first tissue section from each row, which served as control for the following eight tissue sections; these tissue sections were incubated with increasing antibody concentrations (Figures 1-3 ). The last five tissue sections per row were used to determine the influence of different substances on antibody binding (data not shown). The primary antibody-mediated binding of [ 12SI]-iodinated secondary antibody was calculated by subtracting the binding of secondary antibody to this control section from the binding of the following sections of that row. The data in Figures 1-3 are given as mean f SEM (n = 3).
Three animals per time point were used to study the changes in antibody binding during facial nerve regeneration ( Figures SA and 5B ). Primary antibodymediated binding of the [ '251]-iodinated secondary antibody to the operated and unoperated (control) facial nucleus was determined from three tissue sections per animal (in one of the tissue sections primary antibody was omitted). The ratio of antibody binding of operated to control side was calculated for each individual animal and the statistical significance was determined using a two-tailed, unpaired Student's t-test on the log values of the operated to control ratios.
Mathematical Modeling. In the present study we advance the hypothesis suggesting that only antibodies that establish binding to two tissue antigens are bound firmly enough to withstand the dissociation during the multiple washing steps (see Discussion). The following text derives the equations to allow determination of the amount and the changes in this type in situ bound antibody. The following symbols are used: xo, total antigen (Ag) concentration; x, free (unbound) antigen concentration; y, free antibody (Ab) concentration; [xy], concentration of antibody bound to one tissue antigen (AgAb); and [xzy], concentration of antibody bound to two tissue antigens (Ag2Ab). Furthermore, it was assumed that the binding of the antibody to the first (1) and the second (2) tissue antigens is reversible:
with discrete equilibrium constants K1 (1) and K2 (2).
Under equilibrium conditions, one can then show that
[xy] = Kixy (3), and [XIYI = K2x[xyl (4).
[xzy] = KiK2x2y ( 5 ) .
In addition, the total antigen concentration (xo) is the sum of free antigen (7) is a quadratic equation which can be solved for x, the free antigen concentration: [xzy] = 0.5(xox -[xy]) (9), which can be reformulated as:
[xzy] = 0 . 5~0 -O.Tx(l+Kiy)) (10). Using equation (8), this can be resolved t 0:
[XZY] = 0.5Xo -0. (13). Using a = K2w. b = Kly, equation (13) can be reformulated as:
[xzy] = 0.541 + (1 -J(l+8ab/(l+b2)))/(4ab/(l+b2))) (14). With A = 4ab/(l + b'), equation (14) can be simplified to:
[XZY] = 0.541 + (1 -J(I+ZA))/A) (U), OK.
[X~Y]/XO = 0.5(1 + (1 -J(1+2A))/A) (16). Figure 9 shows the changes in the amount of doubly bound antibody (proportion of maximal binding) as a function of the normalized antibody concentration parameter b (b = Kly) and the a-value (a = Kzxo). In all of the curves shown, the amount of antibody bound to two tissue antigens increases up to a certain antibody concentration yk (yk = UK1, b=1), where it reaches a maximum, regardless ofthe a-value, and then decreases at higher antibody concentrations, forming a bell-shaped curve. These curves are relatively flat at high a-values and become steeper as the a-value decreases. At a (0.03, these curves appear to merge into a default form.
Results

In Situ Bindng Characteristics of Primary and Secondary Antibodies
Specific Primary Antibodies. Four monoclonal antibodies were used. Two were directed against membrane proteins, C3bi com-
Primary Antibody Dilution
Primary Antibody Dilution plement receptor (Ox-42) and major histocompatibility complex Class I antigen (Ox-18), and two against intracellular intermediate filament proteins, glial fibrillary acidic protein (GFAP) and vimentin. One polyclonal rabbit anti-GFAP antibody was also used. Since preliminary data indicated that the expression of the antigens in the facial motor nucleus examined in the present study would reacd a peak 7 days after facial nerve transection, this time point was chosen to study the binding characteristics of the primary and secondary antibodies. The unoperated contralateral facial nucleus served as a specific intra-animal control. The extent of primary antibody binding to the tissue section was detected using the appropriate [ 1251]iodinated secondary antibody. To calculate the specific contribution of the first antibody to the binding of the secondary antibody (this will be referred to as the primary antibody-mediated binding or the PAM binding), the first antibody was routinely omitted on some of the tissue sections (three tissue sections per animal and antibody; Figures 1 and 2). The resulting binding was subtracted from that observed in the presence of the primary antibody. The intrinsic binding of secondary antibody in the absence of preincubation with a primary antibody was not different in the operated and the unoperated contralateral facial nucleus at a 1:300 dilution (the routinely used concentration) of the [ '251]-iodinated sheep anti-mouse secondary antibody. It accounted for approximately 50 pglmm3 or 15% of the total binding when (using a 1:6400 dilution of Ox-42 primary antibody was used. As shown in Figure 1A for the Ox-42 antibody, this PAM binding of [ 1251]-iodinated secondary antibody to the 7-day operated facial nucleus rapidly increased with the increasing concentration of the primary antibody, reaching a plateau of approximately 250 pg/mm3 at 1:6400 to 1:lOO dilution and then rapidly decreasing to 138 * 24 pglmm3 (mean f SEM; n = 3) at 1:25 dilution. The PAM binding to the unoperated facial nucleus increased more slowly, reaching a peak of 128 f 14 pglmm3 at 1:lOO dilution and decreasing moderately at 1:25 dilution. Days after facial nerve cut Mathematical Analysis. In theory, this relatively complicated pattern of PAM binding to the operated and unoperated facial nuclei could be explained by postulating the presence of two binding components: a side-independent component present in equal amounts on the operated and unoperated side, and a second, unequally distributed side-dependent component which is responsible for the difference in the antibody binding between the operated and the unoperated side. This second component should be proportional to the difference in PAM binding between the operated and unoperated facial nucleus, since subtraction of the PAM binding to the unoperated side from that on the operated side will remove the side-independent component. This difference in PAM binding between the operated and the unoperated side will be further referred to as the differential PAM binding. Figure 1B shows the concentration dependence of the differential PAM binding using Ox-42 antibody. Like the PAM binding to the operated facial nucleus, the differential PAM binding rapidly increased with increasing concentration of Ox-42, reaching a peak of 205 f 4 pg/mm3 at 1:6400 dilution and then steadily decreasing with further concentration of the primary antibody to less than 20% of the peak values (37 * 9 pg/mm3) at 1:25 dilution. Interestingly, there was a very good linear correlation between PAM binding to the operated facial nucleus and the differential PAM binding for the lowest four concentrations of the primary antibody (1:409,600 to 1:6400 dilutions), with a regression factor of 1.337 (PAM vs differential PAM binding, r2 = 0.99). This very close correlation disappeared at higher antibody concentrations (over the whole concentration range, r2 = 0.77). Similarly, very good correlation was also observed between PAM binding to the unoperated facial nucleus and the differential PAM for the lowest four concentrations (1:409,600 to 1:6400 dilutions) of the primary antibody (r2 = 0.99, regression factor 0.338). No correlation was observed, however, over the whole concentration range (r2 = 0.00). Figure 1C graphically summarizes these data by showing the PAM binding to the operated and unoperated facial nuclei fitted against the differential PAM binding multiplied with the appropriate regression factor. At concentrations of 0 x 4 2 antibody above the 1:6400 dilution, the difference between the actual PAM binding to the operated or unoperated facial nucleus and the fit rapidly increased. The difference is shown in Figure ID , and could represent the side-independent component. In addition, it could be fitted by a simple saturation curve, with a Bm, of 103 pg/mm3 and half-maximal saturation at a 1:270 dilution of the Ox-42 antibody.
Concentration Dependence of PAM Binding with Ox-18, GFAP, and Vimentin Antibodies. Figures 2A, 2C , 2E, and 2G show the PAM binding to the 7-day operated and the unoperated facial nucleus with Ox-18, vimentin, and GFAP. As in Figure lA , at low concentrations of primary antibody the PAM binding to the operated facial nucleus increased more rapidly. A clear peak of the differential PAM binding was observed for the Ox-18 antibody at 1:1600 dilution and for the rabbit anti-GFAP antiserum at 1400 dilution ( Figures 2B and 2H , respectively). An apparent peak was also observed for the vimentin antibody at 1:lOO dilution in (Figure 2D) but not for the monoclonal GFAP antibody ( Figure 2F) . The data on the concentration dependence of the differential PAM binding using the different antibodies are summarized in Table 1 .
Nonspecific Primary Antibodies. The concentration dependence of PAM binding using non-immune mouse and rabbit serum and purified mouse IgG is shown in Figures 3A-3C . Interest- ingly, there was no consistent difference between the PAM binding to the unoperated and the 7-day operated contralateral facial nucleus. Furthermore, like the side-independent component of Ox-42 binding shown in Figure ID , these PAM binding curves could be fitted using standard one-site saturation curves with half-maximal saturation at 1:160 and 1:lOOO dilution for the non-immune mouse serum and non-immune rabbit serum, respectively, and at 20 pg/ml for the purified mouse IgG. Secondary Antibody. As shown above in Figures 1 and 2 , with the increasing concentration of primary antibodies the apparent binding frequently reached a maximum, where a further increase in antibody concentration led to a decrease in the binding parameter. To test the range at which the [1251]-iodinated sheep antimouse secondary antibody can be safely used, tissue sections were pre-incubated with the Ox-42 antibody at 1:6000 dilution, followed by increasing concentrations of the secondary antibody (1:7290 to 1:lO dilution). As shown in Figure 3D , the binding of the secondary antibody to the 7-day operated and the unoperated facial nucleus increased linearly with increasing antibody concentration. Approximately three-fold higher binding was observed to the operated facial nucleus throughout the concentration range used. There was also no apparent saturation of the antibody binding, suggesting that the [ 1251]-iodinated secondary antibody could be used throughout the concentration range. In addition, the 1:300 dilution used in Figures 1-5 falls in the middle of this concentration range.
Concentration Dependence of Primary Antibodies with Enzyme Immunohistochemistry. To localize the side-independent and the side-dependent components postulated in Figures 1C and ID, the tissue sections were incubated with Ox-42 and Ox-18 antibodies at two different concentrations: at a concentration just below the peak differential PAM binding (1:8000 dilution for the Ox-42 and 1:2000 dilution for the Ox-18 antibody) and at a second concentration where the differential PAM binding disappeared almost completely (1:25 dilution for the Ox-42 and 1:lOO dilution for the Ox-18 antibody). The binding of the primary antibodies was visualized with an ABC enzyme histochemistry kit. As shown in Figure  4 , the pattern of immunostaining changes dramatically when using low ( Figures 4A, 4B , 4E, and 4F) and high ( Figures 4C, 4D , 4G, and 4H) concentrations of primary antibodies. At a low concentration of 0 x 4 2 antibody (1:8000 dilution), there was moderate staining of microglial cells in the unoperated facial nucleus ( Figure 4A ) and a very massive staining on cells surrounding the neurons and in the neuropil of the 7-day operated facial nucleus ( Figure 4B ). At high concentration (1:2 5 dilution), heavy labeling was observed on the neuronal perikarya both on the unoperated ( Figure 4C ) and the operated side ( Figure 4D ), whereas the immunostaining present in the neuropil of the operated side ( Figure 4B ) disappeared. A similar change was also observed for the Ox-18 antibody. At low concentration (1:2000 dilution) this antibody showed labeling of capillaries on the unoperated side ( Figure 4E ) and additional neuropil staining in the 7-day operated facial nucleus ( Figure 4F ). Again, this pattern disappeared at the high concentration of the Ox-18 antibody (1:lOo dilution), while heavy immunostaining was observed on the neuronal perikarya on the unoperated and operated side ( Figures 4G and 4H, respectively) . There was also moderate to strong labeling of glial cell bodies on the unoperated and the operated side: on the operated side, a fraction of these cells aggregated around the heavily stained neurons. These data suggest that the sideindependent component of primary antibody binding is localized to neuronal perikarya and glial cell bodies and that this binding site does not change during facial nerve regeneration. As shown in Figures 41 and J , omission of the of the primary (Figure 41 ) or the secondary antibody ( Figure 4J ) resulted in complete disappearance of the enzyme immunohistochemistry.
Changes in Primary Antibody Binding afer Facial Nerve Cut
In the second part of this study we followed the changes in the binding of four primary antibodies (Ox-42, Ox-18, anti-vimentin, and monoclonal anti-GFAP antibodies) in the regenerating facial nucleus with quantitative in situ autoradiography ( Figure 5 ) and enzyme immunohistochemistry ( Figures 6 and 7) . The concentrations of primary antibodies used were also chosen to be equal to or below those with maximal differential PAM binding (1:6400 dilution for the Ox-42, 1:1600 dilution for the Ox-18, and 1:100 dilution for the anti-vimentin and anti-GFAP monoclonal antibodies) to minimize the contribution of the side-independent component of the PAM binding.
Quantitative Changes in Antibody Binding. As shown in Figures  5A and 5B , the relative PAM binding to the operated facial nuclei (operated to control ratio of the PAM binding) increased with all of the four antibodies used. Interestingly, Ox-42 and anti-GFAP antibodies showed a gradual increase in immunoreactivity, rising to a peak of approximately sixfold increase (Ox-42) and twofold increase (GFAP) at 7 days after facial nerve cut, and then gradually decreasing between 7 and 21 days. In contrast, both Ox-18 and antivimentin antibodies showed a more delayed increase at Day 2, followed by a rapid rise to a plateau of approximately 3.5-fold increase (Ox-18) and twofold increase (vimentin) at 4-7 days postoperatively and then rapidly decreasing to normal levels at 21 days postoperatively. In general, the changes observed using quantitative in situ autoradiography reflected those revealed by enzyme immunohistochemistrv, shown in Figures 6 and 7 and detailed below.
Ox-42 Immunoreactivity. With Ox-42 antibody, only moderate immunoreactivity was localized to the resident microglia in the unoperated normal facial motor nucleus ( Figure 6A) . Axotomy led to a strong increase in the staining intensity and the number of labeled cells (see Figure 6C ), reaching a maximum at 7 days after facial nerve cut ( Figure 6E) , with particularly heavy labeling on cells surrounding the neuronal perikarya. There was also a gradual decrease in staining intensity between 7 and 21 days postoperatively ( Figure 6G ).
Ox-18 Immunoreactivity. In the normal facial nucleus, the predominant immunostaining was observed on the capillaries, with diffuse labeling of the neuropil (Figures 4E and 6B) . Axotomy led to a relative decrease in capillary staining and to a gradual increase in neuropil labeling, with particular accentuation on cells surrounding the neuronal perikarya, with a maximum 4-7 days postoperatively and a rapid decrease thereafter (Figures 6D, 6F, and 6H ). Figure 6 . Time course of 0 x 4 2 (left side) and Ox-18 (right side) immunoreactivity in the facial nucleus at Day 0 (A,B, unoperated) and at (C,D) 2, (E,F) Day 0 ( A B , unoperated) and at (CD) 2, (C.F) 7, and (G.H) 21 days after facial nerve cut. Note the vimentin immunoreactivity both on the capillaries (arrowheads) and on the bigger blood vessels (v) Of the normal facial nucleus. In contrast, most GFAP immunoreactivity is localized on cells surrounding or in contact with the big vessels; a few immunoreactive astrocytes are also present in the neuropil (arrows). Nerve cut leads to a massive increase in vimentin and GFAP immunoreactivity on cells in the facial nucleus neuropil, with a maximum at Day 7 (E,F). Bar = 100 pm.
Vimentin Immunoreactivity. Vimentin immunoreactivity in the unoperated facial nucleus was restricted to the capillaries and to bigger vessels transversing the nucleus (see Figure 7A ). Axotomy led to a moderate increase in immunoreactivity on cells in close proximity to the capillaries 2 days after facial nerve cut ( Figure 7C) , followed at later time points (4-7 days postoperatively) by a massive increase in the number of labeled cells in the regenerating facial nucleus neuropil ( Figure 7E) , and by an almost complete disappearance of neuropil immunoreactivity at 21 days after facial nerve cut ( Figure 7G) . GFAP Immunoreactivity. In the unoperated facial nucleus, strongly immunoreactive astrocytes were present directly surrounding big vessels but only rarely in the facial nucleus neuropil proper ( Figure 7B ). There, the number of labeled cell profiles rapidly increased 2 days after facial nerve cut ( Figure 7D ). This was followed by a further increase in the staining intensity, with a peak 7 days postoperatively ( Figure 7F) , and a gradual, moderate decrease in the staining intensity at 21 days (Figure 7H ).
Discussion
The present study originally set out to delineate the concentration dependence of in situ antibody binding, to determine the optimal antibody concentrations, and then to use this information to monitor in situ the changes in the expression of different antigens during facial nerve regeneration. The facial nucleus was chosen as a model tissue to study the effects of axotomy and regeneration because it is a relatively large, compact, and homogeneous nucleus in which axotomy leads to a massive de novo expression of a variety of antigens and which can be easily axotomized without damage to surrounding central nervous tissue (Kreutzberg et al., 1990) . In contrast to direct CNS injury, previous studies failed to observe infiltration by hematogenous cells in axotomized CNS regions after peripheral nerve injury (cf. Streit et al., 1988) . This is important, since many of these cells carry high levels of Fc receptors (Sternberger, 1986; Moretta et al., 1976; Jones et al., 1973) capable of nonspecific antibody binding (i.e., class-specific, not antigenspecific binding), and the influx of these cells could considerably complicate the quantitative analysis of specific antibody binding in the injured tissue.
Concentration Dependence of Antibody
Binding In Situ
The quantitative analysis described in the present study strongly suggests that the antigen-specific antibody binding for most of the tested antibodies follows a bell-shaped curve, with the binding increasing up to a specific antibody concentration and then decreasing. It must be noted that this type of curve was not measured directly, but is a result of indirect immunocytochemistry using [ '2sI]-iodinated secondary antibodies, and was observed after a two-step subtractive approach. First, the intrinsic binding of secondary antibody (i.e., in the absence of pre-incubation with a primary antibody) was routinely subtracted from the total binding. This binding component was not side specific, accounted for approximately 50 pg/mm3 of antibody binding under conditions used in the study, and apparently reflects the antigen-nonspecific binding of the secondary antibody. Subtraction of this component revealed the primary antibody-mediated or PAM binding to the facial nucleus shown in Figures 1-3 and Figure 5 . The second step was the subtraction of this PAM binding in the unoperated contralateral facial nucleus from that on the operated side. The reason for this second subtraction is that, like the secondary antibody, some of the primary antibody molecules could bind nonspecifically (i.e., not antigen specifically) to the tissue. Indeed, as shown in Figures  3A-C , this PAM binding can also be observed using non-immune rabbit and mouse sera or purified IgG from unimmunized mice; like the intrinsic binding of the secondary antibody, this binding to the facial nucleus does not change as result of axotomy. Although some of the PAM binding to the unoperated facial nucleus is undoubtedly antigen specific (this is strongly indicated by enzymatic immunohistochemistry), this second antigen-specific component does not change significantly in the unoperated nucleus after axotomy of the contralateral side (compare Figures 4A and 6A and Figures 4E and 6B ). Subtraction of PAM binding to the unoperated side from that of the operated side may therefore represent the antigen-specific antibody binding to those antigens that are newly expressed after axotomy (since the antigen-nonspecific binding is apparently equal on both sides, this subtraction should remove this nonspecific binding component). As shown in Figures  1B, 2B , and 2H, the resulting antibody binding curve was clearly bell-shaped for the Ox-42 and Ox-18 monoclonal antibodies and for the polyclonal anti-GFAP rabbit antiserum. Similar data were also observed using polyclonal antibodies against synapsin and synaptophysin (Raivich and Kreutzberg, unpublished observations) .
We did not observe a clear bell-shaped curve for the monoclonal vimentin antibody, and in the case of the differential PAM binding for the monoclonal anti-GFAP antibody the binding still increased at the lowest dilution of 1:25. This could be due to the relatively low antibody concentration in the stock solution (40 pg/ml) of the monoclonal GFAP and vimentin antibodies, which is 200-fold lower than that of 0 x 4 2 or Ox-18 antibodies. As shown in Table 1 , the concentration of monoclonal antibodies with peak differential PAM binding ranged from 0.4 to 5 pglml, or between approximately 2.5 and 30 nM IgG 000) . Although in the case of the polyclonal anti-GFAP antiserum the peak concentration was approximately 25 pg/ml, assuming that 30% of the immunoglobulins were directed against GFAP (which would make it a good antiserum) and that the population of specific immunoglobulins was largely made up of only three major types of antibody clones, the effective concentration would be about 2.5 pg/ml. Since two or three concentration steps above the peak concentration are necessary to demonstrate conclusively a bell-shaped binding curve, at least 80 pg/ml of immunoglobulin (i.e., 42.5 x 2.5 pglml) would be needed on tissue sections in the case of the anti-GFAP monoclonal antibody. This is higher than that in the stock solution available for this study. Similar constraints may also apply for the [ 1251]-iodinated secondary antibodies. In that case, the final antibody concentration in the stock solution was only 6 pg/ml, which could explain the absence of saturation in the binding of the secondary antibody shown in Figure 3D . With hindsight from the data described, the immunoglobulin concentration in the stock solution of a specific antibody appears to be an important limitation that must be considered when the concentration dependence of in situ antibody binding is described. 
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A Antigen Figure 8 . A schematic diagram to explain the concentration dependence of in situ antibody binding. (A) At a very low concentration of antibody, both F(ab) parts of the antibody bind to tissue antigens (left side), producing a stable double binding of the antibody to the tissue that does not dissociate during and after the washing procedure (right side). (e) At moderate antibody concentrations, some antbodies bind to antigens but some find only single antigens still available, forming kinetically unstable binding. These antibodies dissociate during the washing procedure (right side). (C) At very high antibody concentrations, almost all of the antibodies bind only to single antigens because of the intense competition between the antibodies in surplus for the limited number of antibody binding antigens. Under these conditions, the tissue binding of antibodies is unstable and dissociates during washing.
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Assuming that the bell-shaped antibody binding curve is a general phenomenon, how could it be explained? A similar concentration dependence of immunohistochemical staining has been observed by Bigbee et al. (1977) with the three-step peroxidase-antiperoxidase (PAP) method. These authors showed that excessive concentrations of the primary antiserum led to a disappearance of specific staining. They attributed this phenomenon to the possibility that if the concentration of the first antibody is too high, the second antibody will preferentially react with the first via both F(ab) components, so that nothing would be available to cross-link it to the PAP complex. This interpretation, however, is not applicable to the present data, since in our case the secondary antibody is labeled either with [1251] or biotin, so that in both cases it will be detected if it binds to the tissue-bound primary antibodies. There-
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Normalized Antibody Concentration Figure 9 . Concentration dependence of antibody binding in a two-site model. The antibody binding at different concentrations is given as a proportion of maximum antibody binding. Note the bell-shaped type of the binding curves. The antibody concentration (X-axis) was normalized by multiplying it with equilibrium constant K1 (b = antibody concentration x Kl). Maximal antibody binding is observed at l / K l (b = 1). The a-values were chosen arbitrarily and rep resent the product of the tissue antigen concentration and the equilibrium constant Kz.
fore, the present data suggest that the concentration dependence of primary antibody binding must be explained by the binding properties of the primary antibodies themselves. In theory, this bell-shaped curve could be generated if two simple saturation curves with the same absolute number of binding sites but different affinities were subtracted from each other. However, this hypothesis could not fully explain the shape of the PAM binding curve to the operated facial nucleus shown in Figures 1A  and 2A . In addition, Figure 4 shows that the normal pattern of immunolabeling completely disappears at a high antibody concentration and is replaced by a side-independent perikaryal staining, clearly suggesting that the decrease in antibody binding is real and not just a mathematical construct. A more likely explanation, illustrated in Figure 8 , would be that the stability of the in situ antibody binding depends on the antibody being able to bind two tissue antigens at the same time using both F(ab) components of the antibody. In contrast, binding to only one antigen would make the antibody liable to rapid dissociation during the washing procedure (see, e.g., Larsson and Schwartt, 1977) , and also during the incubation with the secondary antibody. At low antibody concentrations, there would be a large surplus of tissue antigen ensuring that almost all of the antibodies bound could engage in the stable double binding. With increasing antibody concentration, fewer free antigens would be available to antibodies that have already bound to one of the tissue antigens, leading to a decrease in the absolute amount of antibodies with double binding, the type of antibody binding that would be able to withstand the washing procedure. The mathematical derivation of the binding characteristics for this type of antibody binding is shown above in the mathematical modeling section of Materials and Methods and describes a set of bellshaped curves (see Figure 9) . Overall, this assumed difference in dissociation properties between antibodies binding to one and to two antigens offers a relatively simple explanation for the bell-shaped form of in situ antibody binding and should be tested in a future study. Interestingly, preliminary experiments using directly iodinated primary antibody (Ox-42) showed a striking difference in the dissociation properties of specifically bound antibody, depend- The immunoglobulin concentrations in the stock solution were either directly given by the manufacturer (monoclonal anti-vimentin antibody, monoclonal and polyclonal anti-GFAP antibodies) or were calculated by multiplying the indicated protein concentration and percent immunoglobulin in the ascites fluid (Ox-18 and Ox-42 antibodies).
ing on the antibody concentration in the incubation solution during binding (Raivich et al., unpublished observations) . There was very little dissociation (<8% in 2 hr) of specific binding attained at low antibody concentrations (1:18,000-1:6000 dilution), but it rapidly increased with higher antibody concentrations (70% at 1:225 dilution).
One main conclusion is that increasing concentrations of primary antibodies not only can increase the nonspecific binding but can also compromise the antigen-specific immunostaining; the use of antibodies is therefore only recommended at concentrations at or below the antibody-specific concentration of maximal differential PAM binding in the facial nucleus or a similar parameter when a different tissue is used. This is not a big problem when working with the relatively diluted antibodies such as the monoclonal antivimentin or anti-GFAP antibodies used in the present study, or with unconcentrated hybridoma supernatants, but it does occur with the use of ascites, hyperimmune antisera, or concentrated affinity-purified antibody solutions.
Comparison of Immunohistochemistry Using Enzymatic and Quantitative Autoradiography Methods
As shown in the present study, there is good correlation between the two methods, with respect to both concentration dependence of antibody binding and the changes occurring during facial nerve regeneration. Overall, however, the types of questions that can be answered with the two methods are different, although there is some overlap. For example, enzymatic immunohistochemistry is faster in detecting significant changes such as the de novo expression of the GFAP and vimentin antigens during facial nerve regeneration. The main advantage of quantitative autoradiographic immunohistochemistry is primarily technical. It is more suited to characterize the binding properties of antibodies in situ to specific tissue antigens or to delineate the technical conditions needed for optimal immunohistochemical results. It also offers a clear advantage in detecting changes in antigen expression when the tissue or cells studied are already specifically immunolabeled and the problem is not whether cells or tissue gain or loss immunoreactivity (all or none situations) but whether there is a significant, quantifiable change in their antigen expression. Although similar data could also be obtained using the radioimmunoassay, ELISA, or Western blot techniques, the main advantages of quantitative in situ bind-ing are that it avoids the problems associated with variability in antigen recovery during the extraction procedure and enables a battery of different antibodies to be tested on adjacent sections of a small tissue sample obtained from the same animal.
In summary, the present study has described the concentration dependence of in situ antibody binding using antibodies against MHC Class I, CR3 complement receptor, GFAP, and vimentin, and has quantified the changes that occur in antibody binding in the regenerating rat facial nucleus. Interestingly, the majority of antibodies revealed an apparently bell-shaped curve of antibody binding to tissue sections, which could suggest a two-site model for in situ antibody binding. Furthermore, there was a close correlation between enzyme immunohistochemistry and quantitative in situ antibody binding, with respect to both concentration dependence and the changes during facial nerve regeneration. Overall, the data presented suggest that quantitative immunohistochemistry could be used in two ways to study the binding kinetics of specific monoclonal or polyclonal antibodies and to monitor quantitatively the changes in antigen expression induced by different pathological stimuli and their pharmacological modification.
